Arrowhead Pharmaceuticals news

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals reported a GAAP loss of $18.506 million for 6 months of fiscal year 2022, down 2.5 times from $47.55 million in the previous year. Revenue increased 2.3 times to $179.244 million from $54.113 million a year earlier.

Arrowhead Pharmaceuticals

The loss of Arrowhead Pharmaceuticals under GAAP for 3 months of fiscal year 2022 was $62.87 million, a 3-fold increase from $20.732 million in the previous year. Revenue increased 28.8% to $27.439 million from $21.303 million a year earlier.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals' GAAP loss for fiscal year 2021 was $140.848 million, up 66.6% from $84.553 million in the prior year. Revenue increased 57.2% to $138.287 million compared to $87.992 million a year earlier.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals reported a GAAP loss of $77.474 million for 9 months of fiscal year 2021, up 2.1 times from $36.12 million in the prior year. Revenue increased 24.4% to $100.004 million from $80.359 million a year earlier.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals reported a GAAP loss of $47.55 million for the six months of fiscal year 2021, up 2.1 times from $22.509 million in the prior year. Revenue increased 2.1% to $54.113 million compared to $52.983 million a year earlier.

Arrowhead Pharmaceuticals

The loss of Arrowhead Pharmaceuticals under GAAP for the 3 months of fiscal year 2021 was $20.732 million, up 7.6 times from $2.673 million in the previous year. Revenue decreased 27.7% to $21.303 million from $29.455 million a year earlier.

Arrowhead Pharmaceuticals

Loss of Arrowhead Pharmaceuticals under GAAP for the fiscal year 2020 amounted to $84.553 million, against a profit of $67.975 million in the previous year. Revenue decreased by 47.9% to $87.992 million against $168.796 million a year earlier.

Arrowhead Pharmaceuticals

Arrowhead and Takeda will jointly develop ARO-AAT to treat alpha-1 antitrypsin-associated liver disease. If successful, the companies will license the drug in the U.S. and share the 50/50 profit. Outside the U.S., Takeda will become a major supplier of ARO-AAT. Closing the deal is dependent on the completion of an antitrust review.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals incurred a GAAP loss of $36.121 million in the 9 months of fiscal 2020, compared to a profit of $56.27 million in the previous year. Revenues decreased by 36% to $80,359 million compared to $125,503 million a year earlier.